These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31743394)

  • 1. Effect of Antimalarial Drugs on the Immune Response to Intramuscular Rabies Vaccination Using a Postexposure Prophylaxis Regimen.
    Endy TP; Keiser PB; Cibula D; Abbott M; Ware L; Thomas SJ; Polhemus ME
    J Infect Dis; 2020 Mar; 221(6):927-933. PubMed ID: 31743394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.
    Li R; Li Y; Wen S; Wen H; Nong Y; Mo Z; Xie F; Pellegrini M
    Hum Vaccin Immunother; 2015; 11(2):435-42. PubMed ID: 25692350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination.
    Soentjens P; De Koninck K; Tsoumanis A; Herssens N; Van Den Bossche D; Terryn S; Van Gucht S; Van Damme P; Van Herrewege Y; Bottieau E
    Clin Infect Dis; 2019 Aug; 69(5):797-804. PubMed ID: 30566636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis.
    Endy TP; Keiser PB; Wang D; Jarman RG; Cibula D; Fang H; Ware L; Abbott M; Thomas SJ; Polhemus ME
    J Infect Dis; 2020 Apr; 221(9):1494-1498. PubMed ID: 31802120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
    Recuenco S; Warnock E; Osinubi MOV; Rupprecht CE
    Vaccine; 2017 Aug; 35(34):4315-4320. PubMed ID: 28688782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India.
    Sudarshan MK; Narayana DH; Madhusudana SN; Holla R; Ashwin BY; Gangaboraiah B; Ravish HS
    Hum Vaccin Immunother; 2012 Aug; 8(8):1077-81. PubMed ID: 22699446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen.
    Madhusudana SN; Sanjay TV; Mahendra BJ; Suja MS
    Int J Infect Dis; 2004 May; 8(3):175-9. PubMed ID: 15109593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Houillon G
    Vaccine; 2019 Apr; 37(16):2268-2277. PubMed ID: 30890382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices.
    Rupprecht CE; Briggs D; Brown CM; Franka R; Katz SL; Kerr HD; Lett SM; Levis R; Meltzer MI; Schaffner W; Cieslak PR;
    MMWR Recomm Rep; 2010 Mar; 59(RR-2):1-9. PubMed ID: 20300058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis.
    Ravish HS; Vijayashankar V; Madhusudana SN; Sudarshan MK; Narayana DH; Andanaiah G; Ashwin BY; Rachana AR; Shamanna M
    Hum Vaccin Immunother; 2014; 10(8):2433-7. PubMed ID: 25424951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.
    Manning SE; Rupprecht CE; Fishbein D; Hanlon CA; Lumlertdacha B; Guerra M; Meltzer MI; Dhankhar P; Vaidya SA; Jenkins SR; Sun B; Hull HF;
    MMWR Recomm Rep; 2008 May; 57(RR-3):1-28. PubMed ID: 18496505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.
    Zhang X; Zhu Z; Wang C
    Clin Vaccine Immunol; 2011 Sep; 18(9):1477-9. PubMed ID: 21752947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers".
    Ranney M; Partridge R; Jay GD; Rozzoli DE; Pandey P
    J Travel Med; 2006; 13(6):329-33. PubMed ID: 17107424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.
    Ashwath Narayana DH; Madhusudana SN; Sampath G; Tripathy RM; Sudarshan MK; Gangaboraiah ; Ravish HS; Satapathy DM; Gowda G; Holla R; Ashwin BY; Padhi A; Manjula S; Patel PM
    Hum Vaccin Immunother; 2014; 10(1):120-5. PubMed ID: 24030586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine.
    Gherardin AW; Scrimgeour DJ; Lau SC; Phillips MA; Kass RB
    J Travel Med; 2001; 8(3):122-6. PubMed ID: 11468113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study.
    Cantaert T; Borand L; Kergoat L; Leng C; Ung S; In S; Peng Y; Phoeun C; Hing C; Taing CN; Saman M; Ong S; Mey C; Choeung R; Ly S; Dussart P; Bourhy H; Tarantola A
    Lancet Infect Dis; 2019 Dec; 19(12):1355-1362. PubMed ID: 31570311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.